mTOR inhibition with temsirolimus causes acute increases in glomerular permeability, but inhibits the dynamic permeability actions of puromycin aminonucleoside

American Journal of Physiology - Renal Physiology

Volumn 308, Issue 10, 2015, Pages F1056-F1064

  Axelsson, Josefin ^a   Rippe, Anna ^a   Rippe, Bengt ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Glomerular endothelium; Glomerular filtration; Podocytes; Proteinuria; Transplantation

Indexed keywords

ANGIOTENSIN II; FICOLL; MAMMALIAN TARGET OF RAPAMYCIN; PUROMYCIN AMINONUCLEOSIDE; REACTIVE OXYGEN METABOLITE; TEMPOL; TEMSIROLIMUS; AMINE OXIDE; MTOR PROTEIN, RAT; RAPAMYCIN; SPIN LABELING; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME INHIBITION; FLUID FLOW; GEL PERMEATION CHROMATOGRAPHY; GLOMERULUS FILTRATION; HEMODYNAMIC PARAMETERS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY PROXIMAL TUBULE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PLASMA; PRIORITY JOURNAL; RAT; ULTRAFILTRATION; URETER; URINE; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL MODEL; ANTAGONISTS AND INHIBITORS; CELL MEMBRANE PERMEABILITY; CYTOLOGY; DRUG EFFECTS; GLOMERULUS; GLOMERULUS FILTRATION RATE; PHYSIOLOGY; SPIN LABELING; TIME; WISTAR RAT;

ANGIOTENSIN II; ANIMALS; CELL MEMBRANE PERMEABILITY; CYCLIC N-OXIDES; GLOMERULAR FILTRATION RATE; KIDNEY GLOMERULUS; MALE; MODELS, ANIMAL; PUROMYCIN AMINONUCLEOSIDE; RATS; RATS, WISTAR; SIROLIMUS; SPIN LABELS; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84930833184     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00632.2014     Document Type: Article

References (54)

1. Asgeirsson D, Venturoli D, Rippe B, Rippe C. Increased glomerular permeability to negatively charged Ficoll relative to neutral Ficoll in rats. Am J Physiol Renal Physiol 291: F1083–F1089, 2006.
2. Axelsson J, Mahmutovic I, Rippe A, Rippe B. Loss of size selectivity of the glomerular filtration barrier in rats following laparotomy and muscle trauma. Am J Physiol Renal Physiol 297: F577–F582, 2009.
3. Axelsson J, Rippe A, Sverrisson K, Rippe B. Scavengers of reactive oxygen species, paricalcitol, RhoA and Rac-1 inhibitors and tacrolimus inhibit angiotensin II induced actions or glomerular permeability. Am J Physiol Renal Physiol 305: F237–F243, 2013.
4. Axelsson J, Rippe A, Venturoli D, Swärd P, Rippe B. Effects of early endotoxemia and dextran-induced anaphylaxis on the size selectivity of the glomerular filtration barrier in rats. Am J Physiol Renal Physiol 296: F242–F248, 2009.
5. Axelsson J, Rippe C, Öberg CM, Rippe B. Rapid, dynamic changes in glomerular permeability to macromolecules during angiotensin II (ANG II) infusion in rats. Am J Physiol Renal Physiol 303: F790–F799, 2012.
6. Axelsson J, Rippe A, Rippe B. Acute hyperglycemia induces rapid, reversible increases in glomerular permeability in nondiabetic rats. Am J Physiol Renal Physiol 298: F1306–F1312, 2010.
7. Axelsson J, Rippe A, Rippe B. Transient and sustained increases in glomerular permeability following ANP infusion in rats. Am J Physiol Renal Physiol 300: F24–F30, 2011.
8. Baas MC, Kers J, Florquin S, de Fijter JW, Homan van der Heide JJ, Bergh Weeman MA, ten Berge IJM, Bemelman FJ. Cyclosporine versus everolimus: effects on the glomerulus. Clin Transplant 27: 535–540, 2013.
9. Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F, Investigators ZS. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of denovo kidney transplants: an open-label, randomised, controlled trial. Lancet 377: 837–847, 2011.
10. Chapman JR, Rangan GK. Why do patients develop proteinuria with sirolimus? Do we have the answer? Am J Kidney Dis 55: 213–216, 2010.
11. Cinà DP, Onay T, Paltoo A, Li C, Maezawa Y, De Arteaga J, Jurisicova A, Quaggin SE. Inhibition of MTOR disrupts autophagic flux in podocytes. J Am Soc Nephrol 23: 412–420, 2012.
12. Daniel C, Ziswiler R, Frey B, Pfister M, Marti HP. Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. Exp Nephrol 8: 52–62, 2000.
13. Diamond JR, Bonventre JV, Karnovsky MJ. A role for oxygen free radicals in aminonucleoside nephrosis. Kidney Int 29: 478–483, 1986.
14. Eid AA, Ford BM, Bhandary B, de Cassia Cavaglieri R, Block K, Barnes JL, Gorin Y, Choudhury GG, Abboud HE. Mammalian target of rapamycin regulates Nox4-mediated podocyte depletion in diabetic renal injury. Diabetes 62: 2935–2947, 2013.
15. Franz S, Regeniter A, Hopfer H, Mihatsch M, Dickenmann M. Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosuppression strategies: an ancillary study from a randomized controlled trial. Am J Kidney Dis 55: 335–343, 2010.
16. Gatault P, Lebranchu Y. Conversion to mTOR-inhibitor-based immunosuppression: which patients and when? Transplant Res 2: S3, 2013.
17. Grahammer F, Wanner N, Huber TB. mTOR controls kidney epithelia in health and disease. Nephrol Dial Transplant 29, Suppl 1: i9 –i18, 2014.
18. Granqvist A, Nilsson UA, Ebefors K, Haraldsson B, Nystrom J. Impaired glomerular and tubular antioxidative defense mechanisms in nephrotic syndrome. Am J Physiol Renal Physiol 299: F898–F904, 2010.
19. Greka A, Mundel P. Balancing calcium signals through TRPC5 and TRPC6 in podocytes. J Am Soc Nephrol 22: 1969–1980, 2011.
20. Gwinner W, Landmesser U, Brandes RP, Kubat B, Plasger J, Eberhard O, Koch KM, Olbricht CJ. Reactive oxygen species and antioxidant defense in puromycin aminonucleoside glomerulopathy. J Am Soc Nephrol 8: 1722–1731, 1997.
21. Gödel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S, Debreczeni-Mor A, Lindenmeyer MT, Rastaldi MP, Hartleben G, Wiech T, Fornoni A, Nelson RG, Kretzler M, Wanke R, Pavenstadt H, Kerjaschki D, Cohen CD, Hall MN, Ruegg MA, Inoki K, Walz G, Huber TB. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 121: 2197–2209, 2011.
22. Haraldsson B, Nyström J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 88: 451–487, 2008.
23. Haraldsson BS. The endothelium as part of the integrative glomerular barrier complex. Kidney Int 85: 8–11, 2014.
24. Huber TB, Walz G, Kuehn EW. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int 79: 502–511, 2011.
25. Jeruschke S, Buscher AK, Oh J, Saleem MA, Hoyer PF, Weber S, Nalbant P. Protective effects of the mTOR inhibitor everolimus on cytoskeletal injury in human podocytes are mediated by RhoA signaling. PloS One 8: e55980, 2013.
26. Kim DD, Kleinman DM, Kanetaka T, Gerritsen ME, Nivaggioli T, Weber D, Duran WN. Rapamycin inhibits VEGF-induced microvascular hyperpermeability in vivo. Microcirculation 17: 128–136, 2010.
27. Letavernier E, Bruneval P, Vandermeersch S, Perez J, Mandet C, Belair MF, Haymann JP, Legendre C, Baud L. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 24: 630–638, 2009.
28. Lieberthal W, Levine JS. Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications. Am J Physiol Renal Physiol 303: F180–F191, 2012.
29. Lieberthal W, Levine JS. Mammalian target of rapamycin and the kidney. I. The signaling pathway. Am J Physiol Renal Physiol 303: F1–F10, 2012.
30. Lloberas N, Cruzado JM, Franquesa M, Herrero-Fresneda I, Torras J, Alperovich G, Rama I, Vidal A, Grinyo JM. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 17: 1395–1404, 2006.
31. Lund U, Rippe A, Venturoli D, Tenstad O, Grubb A, Rippe B. Glomerular filtration rate dependence of sieving of albumin and some neutral proteins in rat kidneys. Am J Physiol Renal Physiol 284: F1226–F1234, 2003.
32. Marshall CB, Pippin JW, Krofft RD, Shankland SJ. Puromycin aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in vivo. Kidney Int 70: 1962–1973, 2006.
33. McCarthy E, Sharma R, Sharma M, Li JZ, Ge XL, Dileepan KN, Savin VJ. TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol 9: 433–438, 1998.
34. McCarthy ET, Sharma R, Sharma M. Protective effect of 20-hydroxyeicosatetraenoic acid (20-HETE) on glomerular protein permeability barrier. Kidney Int 67: 152–156, 2005.
35. McDonald DM. Endothelial gaps and permeability of venules in rat tracheas exposed to inflammatory stimuli. Am J Physiol Lung Cell Mol Physiol 266: L61–L83, 1994.
36. Nakakura H, Ashida A, Hirano K, Tamai H. Oxidative stress in a rat model of nephrosis can be quantified by electron spin resonance. Pediatr Nephrol 19: 266–270, 2004.
37. Ohlson M, Sörensson J, Lindström K, Blom AM, Fries E, Haraldsson B. Effects of filtration rate on the glomerular barrier and clearance of four differently shaped molecules. Am J Physiol Renal Physiol 281: F103–F113, 2001.
38. Peti-Peterdi J, Sipos A. A high-powered view of the filtration barrier. J Am Soc Nephrol 21: 1835–1841, 2010.
39. Pippin JW, Brinkkoetter PT, Cormack-Aboud FC, Durvasula RV, Hauser PV, Kowalewska J, Krofft RD, Logar CM, Marshall CB, Ohse T, Shankland SJ. Inducible rodent models of acquired podocyte diseases. Am J Physiol Renal Physiol 296: F213–F229, 2009.
40. Rangan GK, Nguyen T, Mainra R, Succar L, Schwensen KG, Burgess JS, Ho KO. Therapeutic role of sirolimus in non-transplant kidney disease. Pharmacol Ther 123: 187–206, 2009.
41. Ravichandran K, Zafar I, Ozkok A, Edelstein CL. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease. Nephrol Dial Transplant 30: 45–53, 2015.
42. Ricardo SD, Bertram JF, Ryan GB. Antioxidants protect podocyte foot processes in puromycin aminonucleoside-treated rats. J Am Soc Nephrol 4: 1974–1986, 1994.
43. Rincon J, Romero M, Viera N, Pedreanez A, Mosquera J. Increased oxidative stress and apoptosis in acute puromycin aminonucleoside nephrosis. Int J Exp Pathol 85: 25–33, 2004.
44. Rippe C, Rippe A, Larsson A, Asgeirsson D, Rippe B. Nature of glomerular capillary permeability changes following acute renal ischemiareperfusion injury in rats. Am J Physiol Renal Physiol 291: F1362–F1368, 2006.
45. Sharma R, Khanna A, Sharma M, Savin VJ. Transforming growth factor-beta1 increases albumin permeability of isolated rat glomeruli via hydroxyl radicals. Kidney Int 58: 131–136, 2000.
46. Sverrisson K, Axelsson J, Rippe A, Gram M, Akerstrom B, Hansson SR, Rippe B. Extracellular fetal hemoglobin induces increases in glomerular permeability: inhibition with 1-microglobulin and tempol. Am J Physiol Renal Physiol 306: F442–F448, 2014.
47. Torras J, Herrero-Fresneda I, Gulias O, Flaquer M, Vidal A, Cruzado JM, Lloberas N, Franquesa M, Grinyo JM. Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage? Nephrol Dial Transplant 24: 3632–3640, 2009.
48. Vassiliadis J, Bracken C, Matthews D, O’Brien S, Schiavi S, Wawersik S. Calcium mediates glomerular filtration through calcineurin and mTORC2/Akt signaling. J Am Soc Nephrol 22: 1453–1461, 2011.
49. Vollenbroker B, George B, Wolfgart M, Saleem MA, Pavenstadt H, Weide T. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 296: F418–F426, 2009.
50. Wang Z, Wei X, Zhang Y, Ma X, Li B, Zhang S, Du P, Zhang X, Yi F. NADPH oxidase-derived ROS contributes to upregulation of TRPC6 expression in puromycin aminonucleoside-induced podocyte injury. Cell Physiol Biochem 24: 619–626, 2009.
51. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 124: 471–484, 2006
52. Yang Y, Wang J, Qin L, Shou Z, Zhao J, Wang H, Chen Y, Chen J. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol 27: 495–502, 2007.
53. Yoshioka T, Ichikawa I, Fogo A. Reactive oxygen metabolites cause massive, reversible proteinuria and glomerular sieving defect without apparent ultrastructural abnormality. J Am Soc Nephrol 2: 902–912, 1991.
54. Zhou J, Brugarolas J, Parada LF. Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1. Hum Mol Genet 18: 4428–4441, 2009.